Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.
Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.
Explore the dynamic advancements in COPD biologic therapies. Prof. Klaus Rabe, MD, Prof. Claus Vogelmeier, MD, and Prof. Wisia Wedzicha, MD, present and analyze the latest clinical data, offering key insights into current and emerging therapeutic strategies for managing COPD.
This infographic outlines how endotyping, phenotyping, and genotyping are interrelated concepts that are crucial for improving the way patients with COPD are characterized and how understanding these concepts can better optimize patient care
Learn how to identify chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation using blood eosinophil (EOS) levels, understand the associated risks, and recognize factors that may influence EOS counts.
Uncover the complex interconnected factors that drive the progressive and worsening vicious cycle of COPD.
Understand the pathophysiology and clinical relevance of mucus plugs in COPD that ultimately contribute to worse outcomes for patients.
This infographic explores the emerging concepts of disease activity, disease stability, and disease control in COPD.
Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality
The infographic provides information about the clinical characteristics used to classify moderate COPD exacerbations and the impact of these events on lung function, future risk, and mortality.
Join Drs. Nicola Hanania, Surya Bhatt, and Celeste Porsbjerg for a session exploring the burden of COPD in patients with type 2 inflammation and review key cytokine pathways and Phase 3 data on emerging biologic therapies.
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.